Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:Ala-Asp-Ser)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST003565 AN005857 Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST003179 AN005221 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST003144 AN005159 On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity Blood Plasmodium falciparum Malaria Monash University LC-MS
ST003036 AN004978 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 Bacterial cells Pseudomonas aeruginosa Bacterial infection Monash Institute of Pharmaceutical Sciences LC-MS
ST002926 AN004798 Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002792 AN004542 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002107 AN003446 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST001304 AN002172 Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii Fibroblast cells Toxoplasma gondii Parasitic infection Monash University LC-MS
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001033 AN001694 Determination of mode of action of anti-malalrial drugs using untargeted metabolomics Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST000546 AN000832 Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium Cells Plasmodium falciparum Malaria Monash University LC-MS
ST000539 AN000819 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) Cells Human Monash University LC-MS
ST000403 AN000643 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes Cells Human Monash Institute of Pharmaceutical Sciences LC-MS
  logo